Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’ July 21, 2026Posted inBiotechnology Novartis has dropped a phase 2-stage radioligand therapy after the candidate disappointed in the clinic. Post navigation Previous Post Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assetsNext PostAgios says adios to sickle cell program over lackluster phase 2 data
